Whole-body (18)F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer

OBJECTIVE: Because of the high risk of secondary primary malignancies in addition to possible distant metastases, whole-body evaluation is critically important in patients with head and neck cancer. We evaluated the clinical usefulness of whole-body (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) before initial treatment. STUDY DESIGN: We performed whole-body FDG PET in 26 patients with head and neck cancer (squamous cell carcinoma, n = 20; salivary gland carcinoma, n = 6) before initial treatment. FDG images were prospectively evaluated, and further imaging studies were performed if required. Final diagnosis for the presence or absence of distant lesions was made by analysis of the pathologic findings of surgical specimens or by analysis of the clinical follow-up data for more than 1 year. RESULTS: PET images showed FDG avid lesions distant from the head and neck area in 3 of 26 patients (11.5%). Two patients were confirmed to have secondary primary cancer (one with colon cancer in the early stage and another with small lung metastasis from postoperative colon cancer). They were diagnosed and treated properly both for the head and neck cancer and the secondary primary cancer. One patient was confirmed to have large lung metastasis from head and neck cancer, and appropriate treatment was selected. CONCLUSIONS: Whole-body FDG PET has a clinical impact on the management of patients with head and neck cancer by detecting secondary primary malignancies as well as distant metastases.     

Positron emission tomography: a promising diagnostic modality for head and neck pathology.

PURPOSE: The purpose of this study is to discuss the advantages of positron emission tomography (PET) imaging in the diagnosis of head and neck lesions. METHODS: To illustrate this diagnostic method, we describe the nuclear medicine basic technique, present 5 cases for comparison of the results between computed tomography (CT) scan and PET, and review the literature. RESULTS: The 5 cases show that PET allows assessment of lesions earlier and more definitively than other diagnostic images. CONCLUSIONS: PET, a nuclear medicine modality, is a promising tool for diagnosis and follow-up of head and neck lesions. PET allows assessment of changes in the tissue before they would be shown by other diagnostic images. This modality permits differentiation between malignant and benign tumors. It also has the capability to distinguish between scar tissue, necrosis, tumor recurrence, and metastatic disease. It allows the assessment of the patient's progress during therapy, making possible an early identification of nonresponders to therapy.     

PET在头颈部肿瘤诊断与治疗中的应用进展

正电子放射断层显像(PET)作为一种功能成像新技术,可以观察人体组织和器官在分子水平的新陈代谢情况。相比于CT、MRI等传统解剖结构成像方法,PET在肿瘤的早期发现、鉴别原发与转移或复发病灶,以及肿瘤分期和放化疗疗效判断等方面具有独特的优势和重要的临床价值。该文介绍目前PET技术在头颈部肿瘤的临床应用现状和诊断效果,并探讨了PET在头颈部肿瘤诊断和治疗的未来发展趋势。     

PET/CT in the evaluation of patients with squamous cell cancer of the head and neck

The purpose of this study was to compare the findings of positron emission tomography (PET) with fused PET and computed tomography (CT) in patients with suspected locoregional and distant head and neck cancer and to evaluate the impact of those findings on clinical management. Studies of 25 patients were retrospectively evaluated. PET findings were classified as malignant, benign or equivocal. PET/CT findings were then similarly classified and the PET-only results were amended accordingly. Comparison of findings was done on lesion and patient levels. A total of 45 foci of increased 18F-fluorodeoxyglucose (FDG) uptake were noted in 18 patients. PET/CT imaging defined anatomic localization of 41/45 lesions and clarified 6/10 equivocal PET findings. Additional information was provided by PET/CT regarding 9/45 (20%) of the lesions. PET/CT significantly affected patient management in 3/25 patients (12%) by limiting the extent of disease in one and excluding viable disease in two others. The accuracy of PET/CT was 88%, the sensitivity 100% and the specificity was 77%. The negative predictive value was 100% in this combined group of patients with locoregional and distant head and neck cancer. PET/CT is highly contributory for initial staging and in the evaluation of patients with suspected recurrent SCC of the head and neck, in whom anatomic imaging is inconclusive due to the locoregional distortions rendered by surgery and radiotherapy.     

Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.

PURPOSE: The aims of this study were to evaluate the use of [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging of primary and recurrent tumors of the head and neck in comparison to routine clinical methods (physical examination, ultrasonography, computed tomography) and to investigate the effect of FDG-PET scanning on therapeutic strategy. MATERIALS AND METHODS: Retrospective analysis of the results of FDG-PET and conventional diagnostic modalities were compared with biopsy results or patient outcome or both. In a period of 6 years, 78 FDG-PET studies were performed on 56 patients; 24 of them before therapy and 54 on suspicion of residual or recurrent tumor. The evaluation of the diagnostic results was performed separately for the primary site and the nodal sites of the neck and for tumor occurrence in the trunk. RESULTS: In detecting the primary site, FDG-PET results reached a sensitivity of 93%, a specificity of 100%, and an accuracy of 94%. In detecting the nodal sites, similar results of 94%, 97%, and 96% were seen, respectively. In detecting tumor occurrence in the trunk, results were 83%, 100%, and 98%, respectively. The McNemar test did not prove any statistically significant difference between FDG-PET and the evaluated conventional methods. When used in conjunction with conventional diagnostic tests, 22% of the PET scans gave important additional information. Finally, 11% of the performed PET scans led to a change in therapeutic planning. CONCLUSIONS: Our results show that FDG-PET is a reliable method to detect tumors in all tumor sites. Therefore, we recommend that FDG-PET scanning be performed routinely as a first diagnostic step in pretherapeutic staging of patients with biopsy-proven head and neck cancer.     

Diagnostic value of navigation-guided core needle biopsy in deep regions of the head and neck with focal FDG uptake on 18F-FDG PET/CT

PurposeThe aim of this study was to evaluate the feasibility and diagnostic accuracy of core needle biopsy (CNB) in patients with focal fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) in deep regions of the head and neck, with the guidance of infrared navigation integrated with PET.Materials and methodsPatients with suspected primary or recurrent malignancies of the head and neck on PET/CT, from June 2016 to December 2018, were included. Before CNB, the region of interest was delineated and the ideal needle entry points, target sites, and a number of trajectories were designed on iPlan CMF 3.0. CNB was performed with the guidance of infrared navigation integrated with PET, according to the pre-plan. Sensitivity and diagnostic accuracy were analyzed by comparing the biopsy results with the final diagnosis.ResultsThirty-one consecutive patients were included. Among the 31 lesions, 18 were skull base, six were infratemporal fossa, and seven were maxillary region. The median values for SUVmax, SUVmean, and MTV were 6.09 (range: 1.43–24.67), 3.41 (range: 0.38–20.96), and 25.83 (range: 3.54–361.94) for the 31 lesions, respectively. Combined needle approaches were employed, including temporal (nine), subzygomatic (19), paramaxillary (11), and retromandibular (16) approaches. The depths of the 31 deep-region lesions, measured from the needle entry site on the skin to the target point, ranged from 1.33 cm to 7.82 cm (median 4.25 cm). There were three non-diagnostic lesions resulting from CNB, and these were all skull base. The diagnostic accuracy was 90.3%, while the sensitivity was 88%. According to the binary logistic regression for the final diagnosis, the only significant parameter was SUVmax.ConclusionWith the guidance of navigation integrated with PET, CNB is a feasible and accurate diagnostic modality, which is also an alternative to open biopsy in patients with suspected primary or recurrent malignancies in deep regions of the head and neck on PET/CT.     

Bronchoscopy screening in primary oral squamous cell carcinoma: a 10-year experience

Squamous cell carcinoma (SCC) in the head and neck is associated with synchronous or metachronous carcinomas of the lung. Preoperative pulmonary screening is advocated and may be done by bronchoscopy, thoracic radiograph, computed tomography (CT), or positron emission tomography (PET) with CT (PET/CT fusion). We evaluated the role of bronchoscopy in patients with primary oral SCC to ascertain the incidence of synchronous malignancies of the lung.     

Case report: fusion of positron emission tomography (PET) and computed tomography (CT) images for image-guided endoscopic navigation in maxillofacial surgery: clinical application of a new technique.

INTRODUCTION: Surgery based on computed tomography (CT) data is becoming increasingly important in the head and neck region. The technique for hardware fusion between positron emission tomography (PET) and computed tomography (CT) has only been established commercially in the last 4 years. The advantages over CT alone are obvious. The surgeon is simultaneously provided with a map of anatomical as well as of functional (metabolic) details. The fused images offer improved localization of malignant lesions and improved targeting of biopsy, especially for small lesions. PURPOSE: A new technique for image-guided tumour localization for maxillofacial surgery based on PET/CT-image fusion is described. PATIENT AND METHOD: A 78-year-old woman was admitted to this department with a tumour of the skull base. Three dimensional fusion of computed CT with positron PET images on a commercially available navigation system is described. After patient-to-image registration, a high-resolution endoscope was calibrated intraoperatively. Image-guided biopsy specimens were taken under direct visual control. CONCLUSION: PET/CT-image fusion proved extremely helpful to navigate the endoscope to the target lesion and to identify the tumour.     

Positron emission tomography in cancer of the head and neck

The use of positron emission tomography (PET) has increased in oncology and in the assessment of head and neck tumours, where it is most useful for recurrent disease. It has good sensitivity and specificity for diagnosis and staging but is generally not necessary except in difficult cases. Quantitative measures of uptake on PET at diagnosis and after treatment do seem to have prognostic value independent of other information about the tumour and so PET may influence management. It also has a role in the identification of an unknown primary site and of synchronous primaries and metastases (often missed by other imaging). Fusion imaging with magnetic resonance (MRI) or computed tomography (CT) adds a new dimension with improved value for each technique.     

头颈鳞癌Glut1的表达与FDG摄取及其相关性研究

目的:研究Glut1的表达与头颈鳞癌的生物学特性、氟脱氧葡萄糖(fluorodeoxglucose,FDG)摄取的相关性。方法:25例头颈鳞癌患者,分为原发组(12例)和复发组(13例),术前均行18F-FDG-PET/CT显像并应用SUV值定量分析FDG的摄取情况,术后对肿瘤组织进行Glut1免疫组织化学染色,半定量分析Glut1的表达水平。结果:所有头颈鳞癌患者均表现为FDG摄取异常,T分级越高或分化越差的肿瘤较T分级低或分化较好的肿瘤SUV值高(P=0.001、0.04);所有病例Glut1染色阳性,原发性头颈鳞癌的Glut1染色分数低于复发性头颈鳞癌(P=0.03),分化较好的肿瘤染色指数低于分化较差的肿瘤(P=0.02),但是SUV值与Glut1染色分数之间未见明显相关性。结论:原发和复发的头颈鳞癌均有FDG的高摄取和Glut1的高表达;SUV对肿瘤的评估有一定参考价值;Glut1有望作为头颈鳞癌不良预后的指标之一,但是FDG的摄取与Glut1的表达没有相关性。     

Laterality on FDG-PET/CT in clinically node-negative early-stage oral squamous cell carcinoma: a retrospective analysis of patients with late neck metastasis

Oral Radiology - This study aimed to assess the role of preoperative 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) for predicting late neck metastasis in...     

Radioimmunodiagnosis of lymph node metastases in head and neck cancer

INTRODUCTION: Reliable staging of the neck remains a diagnostic challenge in head and neck squamous cell carcinoma (HNSCC) patients. Monoclonal antibodies (MAbs) directed against tumour-associated antigens can be used for selective tumour targeting. When labelled with a gamma-emitting radionuclide like 99mTechnetium, such MAbs can be used for tumour detection by radioimmunoscintigraphy (RIS). OBJECTIVE: The aim of this study was to assess the potential of RIS for the detection of lymph node metastases in HNSCC patients. PATIENTS AND METHODS: In 49 patients with HNSCC, who were scheduled to undergo surgery including neck dissection, RIS using 99mTc-labelled squamous cell specific MAb E48 or U36 administered intravenously was compared with clinical palpation, computed tomography (CT), magnetic resonance imaging (MRI) and histopathological outcome. RESULTS: RIS detected lymph node metastases in 35 of 51 positive sides (sensitivity 69%). Interpretation of RIS was correct in 47 of 65 sides (accuracy 72%). Accuracy of palpation, CT and MRI were comparable. Immunohistochemical staining of lymph node metastases missed by RIS showed that the injected MAb had targeted these small tumour deposits but these were not visualized. CONCLUSIONS: RIS at its current stage of development is not superior to CT or MRI for the detection of lymph node metastases. As small tumour deposits were probably not visualized because of the limited sensitivity and/or spatial resolution of the gamma camera, positron emission tomography (PET) using MAbs labelled with positron emitters may improve the detection. As MAb-PET studies in an animal model showed promising results we will soon start a clinical MAb-PET study.     

Positron emission tomography/computed tomography true fusion imaging in clinical head and neck oncology: early experience.

PURPOSE: Positron emission tomography-computed tomography (PET-CT) is a new imaging modality that provides simultaneous functional and anatomic information. Its application in head and neck oncology is still evolving. MATERIALS AND METHODS: Five illustrative cases who were scanned with this technique are presented. RESULTS: The clinical application and impact on clinical management are described and discussed. CONCLUSION: Our experience indicates that PET-CT will assume a more important role than either CT, magnetic resonance imaging, or PET alone in head and neck cancer imaging.     

Recurrent head and neck desmoplastic melanoma with perineural spread along the nervus mandibularis revealed by 18F-FDG PET/CT

This report describes a rare case of recurrent head and neck desmoplastic neurotropic melanoma with perineural spread along the nervus mandibularis. An 87-year-old male presented with a rapidly growing mass on the right side of the chin, 4 years after surgical excision of a desmoplastic non-melanotic melanoma of the tip of the chin, with lymphadenectomy of the right side submental and submandibular areas. A panoramic X-ray showed extensive widening of the mandibular canal compatible with perineural tumour growth. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) images revealed intense pathological uptake in the recurrent tumour mass located in the right lower buccal fold, and linear pathological uptake in the mandibular canal. Although magnetic resonance imaging is considered the standard of reference, recognition of perineural spread on ¹⁸F-FDG PET/CT is important, as it usually leads to a change in patient management from cure to palliation and may avert further diagnostic procedures.     

FDG-PET/CT in staging of clear cell odontogenic carcinoma

Clear cell odontogenic carcinoma (CCOC) is a rare neoplasm; only 75 cases have been reported in the English language literature. They have a tendency for recurrence and a capacity to metastasize. There is very little known regarding the metabolic features of this tumour or the utility of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scans in the staging and follow-up of these tumours. We present two cases of CCOC with their relevant FDG-PET/CT scan findings. The first patient had primary CCOC of the mandible that was FDG-avid, and the other had recurrence of CCOC of the anterior mandible and superomedial orbit that was not FDG-avid. FDG uptake in CCOC appears to be variable. Although FDG-PET/CT is useful in other head and neck cancers and has benefits compared to other imaging modalities, further studies are needed to investigate the sensitivity of FDG-PET/CT in CCOC.     

In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.

BACKGROUND: Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are the standard imaging techniques to evaluate patients with carcinoma in the sinus/nasal area and orbit. The use of positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) in such patients is as yet less well established. PURPOSE: The aim of this study was to assess the clinical impact of PET co-registered with CT (PET/CT). PATIENTS: Evaluation of 21 consecutive patients. METHODS: A retrospective analysis of the whole body PET/CT studies was done. Images were assessed visually without knowing the results of the other imaging technique. Histology and clinical follow-up served to verify lesions. The clinical impact on therapy was assessed together with the physician in charge. RESULTS: All patients underwent PET/CT and CT or MRI for staging (n=9 scans) and restaging (n=17 scans) without treatment between the examinations. PET/CT changed the treatment protocol in 2 patients at staging and in 7 at re-staging. Distant metastases were found in 5 and a secondary tumour in 1 patient. CONCLUSIONS: Whole body PET/CT adds clinically important information to CT or MRI, thus, influencing treatment.     

Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx

The aim of this study was to assess the diagnostic value of integrated whole body positron emission tomography/contrast-enhanced CT (PET/CECT) as a one step examination in the initial staging of oral and oropharyngeal squamous cell carcinoma (OOSCC). Seventy three consecutive OOSCC patients who underwent PET/CECT for initial staging and tumour resection and neck dissection as primary treatment, were included. For each PET/CECT result, the contribution of fluorine-18 fluorodeoxyglucose (¹⁸F-FDG)-uptake and radiologic criteria was assessed. PET/CECT results were correlated to histological specimens obtained with tumour resection and neck dissection. For detecting the primary tumour PET/CECT showed a sensitivity of 96% and for detecting cervical metastases a sensitivity and specificity of 89% and 81%, respectively. In the clinically N0 subgroup (n = 37), PET/CECT showed a sensitivity and specificity of 64% and 81%, respectively. In five of six patients PET/CECT detected a second primary tumour. The results show that the use of diagnostic PET/CECT as a one step examination is a reliable alternative for PET/CT in combination with a separate diagnostic CT in patients with OOSC for initial staging. The need for treatment of the neck in the clinically negative neck should not be based on PET/CECT results only, due to the risk of missing a small metastasis.     

Solitary fibrous tumor of the buccal space resected in combination with coronoidectomy

Solitary fibrous tumor (SFT) is an uncommon spindle-cell mesenchymal tumor of probable fibroblastic derivation that most often occurs in the pleura, where it is typically benign. This report describes a case of a large SFT that arose in the buccal space, and includes computerized tomography, magnetic resonance imaging, and positron emission tomography (PET) findings. (18)F-Fluorodeoxyglucose (FDG) PET axial imaging showed weak abnormal accumulation of FDG in the left buccal region. The tumor was located behind the posterior wall of the maxilla, adjacent to the medial aspect of the coronoid process and was compressed between the coronoid and maxillary alveolar processes. We resected it with the use of a transoral approach in combination with coronoidectomy. Coronoidectomy was chosen because it facilitated safe removal of the tumor by improving its visibility and providing enough working space to resect it through a transoral approach.     

The role of gamma-PET in the evaluation of patients with recurrent squamous cell cancer of the head and neck

Squamous cell carcinoma (SCC) is the most common cancer of the head and neck (HNC). Advanced HNC warrants extensive ablative and reconstructive procedures, significantly altering locoregional anatomy, while radiation treatment further adds to the distortion. Anatomic imaging is therefore often inconclusive in suspected recurrent HNC. Functional imaging with fluorodeoxyglucose-positron emission tomography (FDG-PET) has been reported contributory in the evaluation of patients with SCC. While most reports are from dedicated PET systems, full ring PET is of limited availability and gamma-PET may offer a suitable compromise. The therapeutic impact of gamma-PET in patients with suspected recurrent HNC was retrospectively evaluated. Seventeen patients were evaluated. All had undergone surgery for HNC, 16 also received radiotherapy. gamma-PET scans were compared to anatomic imaging, histopathology and clinical follow-up. The impact of the FDG-PET scan on patient management was then evaluated. Eleven positive findings were confirmed. Two false positives were due to radiation changes, a recognized pitfall. There were no false negatives. Overall accuracy of the 18F-FDG gamma-PET scans was 88% with considerable effect on patient management. Gamma-PET with FDG appears valuable in the evaluation of suspected recurrent HNC, and may provide a suitable alternative when dedicated PET is unavailable.     

Head and neck sarcomas in adulthood: current trends and evolving management concepts

Sarcomas are rare, malignant bone and soft-tissue tumours of mesenchymal origin, and their overall incidence accounts for 1% and 0.2%, respectively, of all malignancies. The aim of this article is to provide a reference on the evolving management concepts and trends of treatment of adult sarcomas of the head and neck in a major head and neck sarcoma centre. Early diagnosis remains a challenge due to non-specific symptomatology. Imaging such as ultrasound (US), magnetic resonance (MRI), computed tomography (CT), and positron emission tomography (PET) CT assist with diagnosis and staging, and biopsy is essential for diagnosis, tumour differentiation, and grading. Staging is dependent on histological grade, size of tumour, and metastasis. Sarcomas spread via the haematogenous route. Adequate clearance of locoregional disease and prevention of distant micrometastases are key to improved disease-free survival outcomes so multimodal treatment at a sarcoma reference centre is imperative. In the head and neck, the treatment for most bone sarcomas is neoadjuvant chemotherapy followed by compartmental resection. The interim tumour response to neoadjuvant chemotherapy is evaluated by PET CT and MRI. Heavy-particle therapy (proton beam) in combination with surgery is increasingly being used to treat otherwise unresectable disease, particularly in children. For soft tissue sarcomas of the head and neck, treatment is complex and depends on grade. Surgery is the principle mode of treatment in low-grade tumours that are amenable to resection. High-grade tumours can be treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. In such cases, the response to the chemotherapy might be used as a guide of potential biological aggressiveness, and has an impact on the planning of the operation and the type and extent of radiotherapy. As a general rule, radiotherapy is reserved for high-grade, advanced soft-tissue sarcomas of the head and neck. Those of bone are radioresistant, and radiotherapy is only administered for palliative purposes when no surgical option exists, an exception being Ewing sarcoma. The role of proton beam therapy is promising, but to our knowledge no long-term data currently exist. The survival advantage of innate immune-modulation remains uncertain for disease in the head and neck.